Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Valeureux is a venture capital fund based in Paris, France, specializing in early-stage deep tech companies. Founded with the mission to support innovative ventures, Valeureux addresses significant challenges in health, climate, and biodiversity. The firm emphasizes long-term partnerships, guiding startups from inception to their full potential.
Currently, Valeureux operates with a team of experts across various fields, including clinical trials, engineering sciences, and medical devices. Although specific metrics such as assets under management (AUM) or fund count are not disclosed, the firm is actively engaged in the European market, particularly in France. Valeureux's commitment to early deep tech investments positions it as a key player in the venture capital landscape.
Valeureux's investment strategy targets early deep tech companies that provide disruptive solutions to major global issues. The firm focuses on sectors such as frontier technology, healthcare, and climate. Investments are made primarily at the pre-seed, seed, and seed-plus stages, allowing Valeureux to engage with startups at critical points in their development.
The organization seeks to identify promising technologies at the research stage, preparing them for subsequent funding rounds. This approach not only supports the growth of innovative companies but also aligns with Valeureux's goal of fostering long-term partnerships. The firm values founders who are committed to addressing pressing challenges and demonstrates a clear vision for their ventures.
Valeureux's portfolio includes notable companies that exemplify its investment focus. One significant investment is CXS Therapeutics, recognized for its success in the healthcare sector. This company highlights Valeureux's commitment to supporting ventures that tackle critical health challenges.
While the portfolio may include additional companies, specific details beyond CXS Therapeutics are not provided. The emphasis remains on early-stage investments that align with the firm's focus on deep tech and innovative solutions.
Philippe Nussbaumer - General Partner. Philippe has extensive experience in venture capital and has led numerous successful investments in deep tech.
Claudio Disma - VC Analyst. Claudio specializes in evaluating early-stage startups and has a background in technology assessment.
Brunetto Santolin - VC Analyst. Brunetto focuses on market research and analysis, contributing to the firm's investment decisions.
Célestine Falise - Market Approach and Sales. Célestine brings expertise in sales strategies for tech startups.
Béatrice Vivier - Director of M&A. Béatrice has a strong background in mergers and acquisitions, enhancing Valeureux's strategic partnerships.
Gaspard de Monclin - Business Lawyer. Gaspard provides legal expertise, ensuring compliance and risk management for portfolio companies.
Annie-Claude Benichou - Clinical Trials. Annie-Claude specializes in clinical trial management, supporting healthcare startups.
Laurent Meilhac - Laser Optics and Medical Devices. Laurent has a background in medical technology, contributing to investments in healthcare.
Daphnée Lucenet - Engineering Sciences and Innovative Models. Daphnée focuses on engineering solutions and innovative business models.
Matthieu Peterschmitt - Electronics and Energy Economics. Matthieu brings expertise in electronics and energy sectors, enhancing the firm's investment strategy.
To pitch to Valeureux, interested parties should visit their website at valeureux.com. It is recommended to include a clear overview of the technology, market potential, and the team behind the startup in the pitch deck.
Valeureux has been actively promoting its investment strategy and portfolio through its website, particularly highlighting its commitment to early deep tech investments. The firm features CXS Therapeutics as a notable success in its portfolio, indicating ongoing engagement with impactful ventures.
As of now, there are no recent announcements regarding new fund raises or leadership changes.
What are Valeureux's investment criteria?
Valeureux invests in early-stage deep tech companies, particularly those addressing significant challenges in health, climate, and biodiversity. The firm focuses on pre-seed, seed, and seed-plus stages.
How can I pitch to Valeureux?
Interested parties can submit their pitches through Valeureux's website at valeureux.com. Specific application forms or email addresses are not provided.
What makes Valeureux different from other VC firms?
Valeureux emphasizes long-term partnerships with its portfolio companies, supporting them from inception through to their full potential. The firm focuses on identifying promising technologies at the research stage.
What is Valeureux's geographic scope?
Valeureux primarily invests in Europe, with a strong focus on the French market.
What is Valeureux's post-investment involvement like?
The firm is committed to supporting its portfolio companies through various stages of development, leveraging its expertise in clinical trials, engineering sciences, and medical devices.
What is the typical check size for investments?
Specific check sizes are not disclosed, but Valeureux focuses on early-stage investments, which typically involve smaller amounts compared to later-stage funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.